| Name | Title | Contact Details |
|---|---|---|
Mike Withers |
Chief Information Officer | Profile |
Michael Withers |
Chief Information Officer | Profile |
Daryl Connell |
Chief Information Officer | Profile |
Seisa Group is a premier full-service medical device manufacturer.
Owens Healthcare is a Redding, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inari Medical is a medical device company pioneering devices for the interventional treatment of vascular thrombi and emboli.
Patient populations deserve better care. We believe this is possible when physicians are empowered with actionable real-time data to make the most informed medical decisions possible. Alio Medical is medical technology company focused on providing peace of mind to dialysis patients through advanced remote monitoring. Alio provides wireless, remote, noninvasive monitoring of end stage kidney disease (ESKD) patients undergoing hemodialysis. Alio monitors dialysis patient blood flow by capturing and transmitting multimodal sensor data at regular intervals using quantitative analysis of optical, mechanical, acoustic, and thermal data related to blood flow and the composition of the blood itself. Alio remote monitoring utilizes a wearable device, the SmartPatch, placed over the patient`s vascular access graft to gather data and transmit it to a Hub located in the patient`s home. The Hub relays this raw data to the Alio Cloud where it is processed and analyzed utilizing Alio`s proprietary algorithms, developed using data collected pre- and post-dialysis in clinical centers in the US and UK. Alio clinically actionable data is accessed by the clinical team via a web-based data portal and the clinical team is alerted if an abnormality in any of a patient`s metrics is detected. Alio is designed to allow the dialysis patient healthcare team to partner effectively and enjoy simpler care coordination as well as more effective management of their patient`s health.
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.